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AbstrAct:
Elucidating the response of breast cancer cells to chemotherapeutic and hormonal 
based drugs is clearly important as these are frequently used therapeutic approaches. 
A signaling pathway often involved in chemo- and hormonal-resistance is the Ras/
PI3K/PTEN/Akt/mTOR cascade. In the studies presented in this report, we have 
examined the effects of constitutive activation of Akt on the sensitivity of MCF-
7 breast cancer cells to chemotherapeutic- and hormonal-based drugs as well as 
mTOR inhibitors. MCF-7 cells which expressed a constitutively-activated Akt-1 gene 
[∆Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen 
(4HT) than cells lacking ∆Akt-1(CA). Cells which expressed ∆Akt-1(CA) were 
hypersensitive to the mTOR inhibitor rapamycin. Furthermore, rapamycin lowered 
the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed ∆Akt-1(CA), 
demonstrating a potential improved method for treating certain breast cancers which 
have deregulated PI3K/PTEN/Akt/mTOR signaling. Understanding how breast 
cancers respond to chemo- and hormonal-based therapies and the mechanisms 
by which they can become drug resistant may enhance our ability to treat breast 
cancer. These results also document the potential importance of knowledge of the 
mutations present in certain cancers which may permit more effective therapies.
IntroductIon
Growth factor receptors are critical for controlling 
the proliferation of cells. Once activated, these receptors 
induce multiple signaling pathways involved in growth, 
prevention of apoptosis, differentiation and other 
fundamental processes. The epidermal growth factor 
(EGF) receptor (EGFR) and isoforms such as HER2 
are also associated with breast cancer development and 
resistance to anticancer agents [1]. The HER2 growth 
factor receptor is frequently amplified in human breast 
cancer and is a target of diverse therapeutic approaches 
as well as an important biomarker [2-4]. Among the 
signaling pathways downstream of these and other 
receptors, the PI3K/PTEN/Akt/mTOR and Ras/Raf/
MEK/ERK pathways have been shown to regulate growth 
and prevent apoptosis and their deregulation is often 
implicated in malignant transformation [5-12]. These 
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pathways also play key roles in the genesis of cancer 
initiating cells (CICs, a.k.a. cancer stem cells) [13-22]. 
The PI3K/PTENAkt/mTOR pathway is frequently 
activated by mutations which may alter sensitivity to 
targeted therapy. The PI3K p110 catalytic subunit gene 
(PIK3CA) is one of the most frequently mutated genes 
in breast cancer [23]. Mutations in the kinase domain of 
PIK3CA will result in activation of Akt and contribute 
to malignant transformation, however the roles of 
these mutations in sensitivity to traditional chemo- and 
hormonal- based therapies and targeted therapies are not 
so well elucidated [24-26]. 
The regulation of Akt activation is complex. Akt is 
a key domino in determining whether a cell will survive 
and proliferate, undergo apoptosis or senescence [27-
40]. Phosphatidylinositol (PI) (3,4)P2 and PI(3,4,5)P3 
produced by class 1A PI3Ks recruit phosphoinositide 
dependent kinase-1 (PDK1) as well as Akt isoforms to 
the plasma membrane by interacting with their pleckstrin 
homology (PH) domains [41-44]. Co-localization of 
PDK1 with Akts at the plasma membrane causes PDK1 
to phosphorylate Akts at a threonine residue (T308) and 
a serine residue (S473). The kinase which phosphorylates 
S473 is believed to be mTORC2, which actually is the 
rapamycin-insensitive complex which lies downstream 
of Akt [44].   Activation of PDK1 and Akt by class 1A 
PI3Ks is negatively regulated by phosphatase and tensin 
homologue deleted on chromosome ten (PTEN) [7, 9, 
44-48]. PTEN removes phosphate groups from PI(3,4)P2 
and PI(3,4,5)P3 added by PI3K as well as from tyrosine 
phosphorylated proteins including focal adhesion kinase 
(FAK) and Shc [7,11,44]. PTEN is a critical tumor 
suppressor gene and another key lynch-pin in regulation 
of this pathway. PTEN is frequently inactivated by various 
genetic mechanisms which results in Akt activation.
Diverse mechanisms regulate PTEN expression 
[10,47-50]. These range from gene deletion, alterations 
in mRNA splicing, subcellular localization or epigenetic 
mechanisms which prevent PTEN transcription. There 
are many microRNAs (miRNAs) which target the PTEN 
gene to inhibit its expression [10,47,51]. Furthermore 
there is a pseudo PTEN gene which serves as a decoy 
to bind and neutralize some of these miRNAs [10,47]. 
Mutations have been reported to occur at PTEN in breast 
cancer at varying frequencies (5-21%). While PTEN is 
deleted in certain cancers, loss of heterozygosity (LOH) 
is probably a more common genetic event (30%) leading 
to changes in PTEN expression [47,52]. PTEN promoter 
methylation leads to low PTEN expression [47]. In one 
study, 26% of primary breast cancers had low PTEN 
levels which correlated with lymph node metastases and 
poor prognoses [53]. PTEN has both plasma membrane 
and nuclear localized activities. Disruption of PTEN 
activity by various mechanisms frequently results in Akt 
activation. Activation of Akt could have vast effects on 
different processes affecting breast cancer drug resistance 
and sensitivity to targeted therapy. 
A consequence of impaired PTEN expression is 
elevated activation of Akt. Elevated Akt activity can have 
many effects on cell growth, such as; the phosphorylation 
and activation/inactivation of transcription factors which 
control pivotal gene expression, the inactivation of 
anti-apoptotic molecules by their phosphorylation and 
subsequent protesomal degradation, or by the regulation 
of translation of key “weak” mRNAs involved in growth. 
One downstream molecule of mTOR is ribosomal S6 
kinase (p70S6K). This kinase regulates the efficiency 
of translation of certain mRNAs and also functions 
in a negative feedback loop to control Akt activity 
[10,44,54-55]. The roles of Akt and p70S6K and other 
molecules are essential for the formation of the eIF4F 
translation complex. The eIF4F complex is necessary 
for the translation of mRNAs containing long 5’UTRs 
which are highly-structured and have an elevated G+C 
content. These mRNAs are considered “weak” mRNAs. 
These “weak” mRNAs often encode genes involved in 
oncogenesis and survival such as c-Myc, Mcl-1, cyclin-D, 
VEGF and survivin. Furthermore p70S6K has important 
roles in autophagy and cellular senescence [56]. 
Akt, mTOR and p70S6K activation have been 
associated with a more severe prognosis in breast and 
other cancers [53,57-64]. Targeting the PI3K/PTEN/Akt/
mTOR pathway may prove effective in various cancer 
therapies [12,54,65-66]. High levels of activated Akt 
expression have been associated with both chemo- and 
hormonal resistance in breast cancer [58-59,67]. Indeed 
some studies have evaluated the effectiveness of targeting 
mTOR in PTEN-negative cells [60]. Cells which express 
high levels of activated Akt may be more sensitive to 
mTOR inhibitors and inhibition of mTOR activity by 
rapamycin may restore their sensitivity to chemo- and 
hormonal based therapies [9,60]. A distinct advantage to 
targeting mTOR with rapamycin is that rapamycin has 
been used many years to treat organ transplant patients 
(especially kidney transplant). Rapamycin is now being 
examined in treatment of certain cancers and in the 
prevention of aging and other diseases including AIDS 
[11-12,68]. 
Previously it was determined that mutated forms 
of Akt and PTEN can induce chemotherapeutic- and 
hormonal-based drug resistance in breast cancer [9,58,67]. 
PTEN mutation which eliminate lipid phosphatase activity 
will result in activated Akt expression which will lead to 
drug resistance and sensitivity to the mTOR inhibitor 
rapamycin [9]. 
In the following studies, the effects enforced 
expression of activated Akt-1 on drug resistance and 
sensitivity to targeted therapy. Inhibitors targeting mTOR 
suppressed drug resistance demonstrating the importance 
of mTOR in chemosensitivity. These experiments 
were performed to understand the effect of common 
chemotherapeutic drugs on anti-apoptotic signaling 
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pathways as well as how these signaling pathways can 
change in drug resistant cells. 
results
effects of constitutively-Activated Akt-1 
expression on the sensitivity of McF-7 cells to 
chemotherapeutic drugs
A means to examine the effects of deregulated 
Akt-1 expression on the sensitivity of MCF-7 cells to 
chemotherapeutic- and hormonal-based drugs is to infect 
MCF-7 cells with a retrovirus encoding a constitutively-
active Akt gene such as ∆Akt-1(CA) [69]. Pools of 
∆Akt-1(CA)-infected MCF-7 cells were recovered after 
selection in medium containing G418 as that is the 
drug that the neoR gene present in the retroviral vector 
encodes resistance to. The ∆Akt-1(CA)-infected cells 
are named MCF7/∆Akt-1(CA). The sensitivities of these 
cells to chemotherapeutic drugs were determined by 
MTT analysis after incubation for 4 days in the indicated 
culture conditions. Figure 1 illustrates the sensitivities of 
the MCF-7 and MCF7/∆Akt-1(CA) cells to doxorubicin, 
etopside and paclitaxel. As an additional control, similar 
experiments were performed with MCF-7 cells transfected 
with the empty neor plasmid, pEGFP (MCF7/EGFP). 
These cells represent a control for cells transfected with 
just a neoR gene. MCF7/EGFP cells were similar in drug 
sensitivity as MCF-7 cells.  
Initially, the ∆Akt-1(CA)-infected cells were about 
2- and 1.5-fold more resistant to doxorubicin (Figure 1, 
Panel A) and etoposide (Figure 1, Panel B) respectively 
than the parental MCF-7 (Table 1). In contrast the 
MCF7/∆Akt-1(CA) cells did not show any difference in 
sensitivity to paclitaxel than the parental MCF-7 cell line 
from which they were derived (Figure 1, Panel C). 
We also isolated ∆Akt-1(CA) cells with increased 
resistance to chemotherapeutic drugs by culturing the cells 
for 4 weeks in medium containing 25 nM doxorubicin. 
These cells were named MCF7/∆Akt-1(CA)DoxR and 
they were 5-fold more frequently recovered from cells 
infected with the ∆Akt-1(CA)-containing virus than from 
control cell lines. The MCF7/∆Akt-1(CA)DoxR cells 
were 6.7- and 3.1-fold more resistant to doxorubicin and 
etoposide respectively than control MCF-7 cells (Figure 
Figure 1: effects of Akt-1 expression on 
chemotherapeutic drug sensitivity. The effects of Akt-
1(CA) expression on sensitivity of MCF-7 cells to: Panel A. 
doxorubicin, Panel b. etoposide and Panel c. paclitaxel were 
examined by MTT analysis after incubation of the cells in the 
indicated concentrations of the drugs. MCF7/∆Akt-1(CA) were 
isolated after infection of MCF-7 cells with a retrovirus encoding 
∆Akt-1(CA) and selection in G418 (geneticin) for 4 weeks. 
MCF7/∆Akt-1(CA)DoxR cells were isolated after selection of 
MCF7/∆Akt-1(CA) cells for 4 weeks in medium containing 
25 nM doxorubicin. The dotted arrow represents where 50% 
inhibition of growth intercepts with the X axis and is used to 
estimate the IC50. The statistical significance was determined by 
the unpaired t test. Comparisons determined to be significant 
are indicated with (***). Panel A. The P value between 
doxorubicin treatment of MCF-7 and MCF7/∆Akt-1(CA) cells 
was 0.0025. The P value between doxorubicin treatment of 
MCF-7 and MCF7/∆Akt-1(CA)DoxR cells was <0.0001. The 
P value between doxorubicin treatment of MCF7/∆Akt-1(CA) 
and MCF7/∆Akt-1(CA)DoxR cells was 0.0003. Panel B. The P 
value between etoposide treatment of MCF-7 and MCF7/∆Akt-
1(CA)DoxR cells was 0.0003. The P value between etoposide 
treatment of MCF7/∆Akt-1(CA) and MCF7/∆Akt-1(CA)DoxR 
cells was 0.001.
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table 1. effects of Activated Akt-1 expression on chemotherapeutic and Hormonal drugs and 
signal transduction Inhibitors Ic50s.1 __________________________________________________________________________
Cell Line Drug Treatment IC50
2 or Change in IC50
3
MCF-7 Doxorubicin 20 nM2
MCF-7/∆Akt-1(CA) Doxorubicin 2 X↑3
MCF-7/∆Akt-1(CA)DoxR Doxorubicin 6.7 X↑3
MCF-7 Etoposide 140 nM2
MCF-7/∆Akt-1(CA) Etoposide 1.5 X↑3
MCF-7/∆Akt-1(CA)DoxR Etoposide 3.1 X↑3
MCF-7 Paclitaxel 10 nM2
MCF-7/∆Akt-1(CA) Paclitaxel -3
MCF-7/∆Akt-1(CA)DoxR Paclitaxel -3
MCF-7 4HT 7 nM2
MCF-7/∆Akt-1(CA) 4HT 4.3 X↑3
MCF-7/∆Akt-1(CA)DoxR 4HT 10 X↑3
MCF-7 Rapamycin 7 nM2
MCF-7/∆Akt-1(CA) Rapamycin 2.5 X↓3
MCF-7/∆Akt-1(CA)DoxR Rapamycin 7 X↓3
1Determined by MTT analysis as presented in Figures 1 and 2. 2IC50 for MCF-7 cells.
 3Comparisons to value 
obtained in MCF-7 cells. - = baseline with MCF-7 cells or no difference compared to MCF-7 cells. X↑ = fold 
increase in IC50. X↓ = fold decrease in IC50.
table 2: effects of combination of chemotherapeutic, Hormone based and signal transduction 
Inhibitors Ic50s.1 ______________________________________________________
Cell Line Drug Treatment Change in IC502
MCF-7 Doxorubicin + 5 nM 4HT 7.5 X↓2
MCF-7/∆Akt-1(CA) Doxorubicin + 5 nM 4HT 10.7 X↓2
MCF-7/∆Akt-1(CA)DoxR Doxorubicin + 5 nM 4HT 8.9 X↓2
MCF-7 Doxorubicin + 1 nM Rapamycin -2
MCF-7/∆Akt-1(CA) Doxorubicin + 1 nM Rapamycin 2.5 X↓2
MCF-7/∆Akt-1(CA)DoxR Doxorubicin + 1 nM Rapamycin 60 X↓2
MCF-7 Etoposide + 1 nM Rapamycin -2
MCF-7/∆Akt-1(CA) Etoposide + 1 nM Rapamycin 1.3 X↓2
MCF-7/∆Akt-1(CA)DoxR Etoposide + 1 nM Rapamycin 2.5 X↓2
MCF-7 4HT + 1 nM Rapamycin 5.8 X↓2
MCF-7/∆Akt-1(CA) 4HT + 1 nM Rapamycin 18.7 X↓2
MCF-7/∆Akt-1(CA)DoxR 4HT + 1 nM Rapamycin 60 X↓2
1Determined by MTT analysis as presented in Figures 3, 4 & 5. 2Comparison with identical cell line treated 
the same day with just single chemotherapeutic- or hormone based drug, averages of 3 experiments (See Figures 
4 and 5 for examples). - = no difference compared to same cell line. X↑ = fold increase in IC50. X↓ = fold decrease 
in IC50. 
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1, Panels A & B). In contrast, no difference in sensitivity 
to paclitaxel was observed (Figure 1, Panel C). The IC50s 
for doxorubicin ranged from approximately 10 to 120 
nM in the doxorubicin sensitive MCF-7 and resistant 
MCF7/∆Akt-1(CA)DoxR cells respectively. The IC50s for 
etoposide ranged from 150 to 600 nM in the doxorubicin 
sensitive MCF-7 and resistant MCF7/∆Akt-1(CA)DoxR 
cells the respectively. In contrast, the IC50s for paclitaxel 
were approximately 10 nM in the doxorubicin sensitive 
MCF-7 and resistant MCF7/∆Akt-1(CA)DoxR cells. 
effects of constitutively-Activated Akt-1 
expression of the sensitivity of McF-7 cells to 
the Hormone-based drug tamoxifen
The effects of the hormonal drug 4-hydroxytamoxifen 
(4HT) were examined on the estrogen receptor positive 
(ER+) MCF-7 and MCF7/∆Akt-1(CA) cells by MTT 
analysis (Figure 2, Panel A). The IC50s for 4HT in the 
ER+ MCF-7 and Akt-transduced cells ranged from 
7 to 200 nM (Table 1). The MCF7/∆Akt-1(CA) cells 
were approximately 4.3-fold more resistant to the 
effects of 4HT than MCF-7 cells. The MCF7/∆Akt-
1(CA)DoxR cells were approximately 10-fold more 
resistant the effects of 4HT than MCF-7 cells (Table 
1). Thus constitutive Akt-1 expression elevated the 
concentration of 4HT required to achieve the IC50. 
effects of constitutively-Activated Akt-1 
expression of the sensitivity of McF-7 cells to 
the mtor Inhibitor rapamycin
Constitutive expression of activated Akt-1 conferred 
increased sensitivity to the mTOR inhibitor rapamycin 
as the IC50s for rapamycin were 2.8- and 7-fold lower 
in MCF-7/∆Akt-1(CA) and MCF-7/∆Akt-1(CA)DoxR, 
respectively, than in MCF-7 cells (Figure 2, Panel B 
and Table 1). The IC50s for rapamycin ranged from 
approximately 1 to 10 nM. MCF-7 cells are inherently 
sensitive to rapamycin, perhaps due to a mutation 
at PIK3CA in this cell line [23]. The doxorubicin-
selected MCF-7/∆Akt-1(CA)DoxR cells were 2.5-fold 
more sensitive to rapamycin than the MCF-7/∆Akt-
1(CA) cells. Thus introduction of activated Akt-1 
into MCF-7 cells conferred increased sensitivity to 
rapamycin and drug resistant MCF-7/∆Akt-1(CA)
DoxR cells were even more sensitive to rapamycin. 
enhancement of doxorubicin Induced-Inhibition 
of Proliferation by Addition of tamoxifen
The abilities to improve chemotherapy by potentially 
lowering dose-associated deleterious side effects were 
examined. Namely, we determined the ability of hormonal-
based therapy to lower the doxorubicin IC50. In this 
particular experiment presented in Figure 3, Panel A, we 
added a constant dose of 50 nM 4HT and different doses 
of doxorubicin to examine the effects on MCF7/∆Akt-
1(CA) cells. It should be pointed out that 4HT by itself, 
like rapamycin, did not totally eliminate viability of the 
cells after 4 days of incubation, as approximately 25% 
relative growth was still observed (Figure 2, Panels A & 
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Figure 2: effects of Akt expression on sensitivity to 
tamoxifen and rapamycin. The effects of ∆Akt-1(CA) 
expression on sensitivity of MCF-7 cells to: Panel A. tamoxifen 
(4HT) and Panel b. rapamycin were examined by MTT analysis 
after incubation of the cells in the indicated concentrations of 
the drugs. The dotted arrow represents where 50% inhibition of 
growth intercepts with the X axis and is used to estimate the 
IC50. The statistical significance was determined by the unpaired 
t test. Comparisons determined to be significant are indicated 
with (***). Panel A. The P value between 4HT treatment of 
MCF7/EGFPc2 and MCF7/∆Akt-1(CA) cells was 0.005. The 
P value between rapamycin treatment of MCF7/EGFPc2 and 
MCF7/∆Akt-1(CA) cells was 0.019.  
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B). In contrast, high concentrations of doxorubicin (>500 
nM) almost totally eliminated the relative growth of the 
cells at sufficient concentrations (Figure 1). As shown in 
Figure 3, Panel A, addition of 50 nM 4HT reduced the 
doxorubicin IC50 approximately 10-fold. Moreover, when 
the doses of doxorubicin required for essentially total 
cell death (>95% inhibition) were examined, a 2-fold 
lower dose of doxorubicin was required (250 vs 500 nM 
doxorubicin) when 4HT was added than in its absence.
Next we examined the effects of a constant, sub-
optimal dose of 5 nM 4HT on the doxorubicin IC50s 
in MCF-7, MCF-7/∆Akt-1(CA), and MCF-7/∆Akt-
1(CA)DoxR cells. 7.5-, 10.7- and 8.9-fold decreases 
in the IC50 for doxorubicin were observed (Table 2). 
These results indicated that suppressing the ER could 
promote the cytotoxic effects of doxorubicin at lower 
concentrations. Moreover, even though the MCF-
7/∆Akt-1(CA) cells required more 4HT to reach the 
IC50 than MCF-7 cells, they remained sensitive to 4HT 
enhancement of doxorubicin and 4Ht Induced 
Inhibition of Proliferation by the mtor Inhibitor 
rapamycin
The abilities to improve chemo- and hormonal-
based therapy by potentially lowering dose-associated 
deleterious side effects were examined. Namely, we 
examined the ability of the mTOR inhibitor rapamycin to 
lower the doxorubicin and 4HT IC50s. In these experiments, 
we used a constant doses of 1 nM mTOR inhibitor and 
different doses of either 4HT or doxorubicin to examine 
the effects on MCF7/Akt-1(CA) cells (Figure 3, Panels 
B and C). Co-addition of constant doses of the mTOR 
inhibitor lowered the doses of doxorubicin and 4HT 
required to obtain the doxorubicin and 4HT IC50s by 2.6- 
and 14-fold respectively. However, even with the mTOR 
inhibitor, 4HT did not totally eliminate the relative growth 
of MCF7/∆Akt-1(CA) cells (Panel C) while doxorubicin 
did (Panel B).
Combinatorial effects on 4HT IC50s were observed 
with rapamycin in MCF-7, MCF7/∆Akt-1(CA) and 
MCF7/∆Akt-1(CA)DoxR cells (Table 2). The highest 
level of rapamycin-mediated suppression of the 4HT IC50s 
was observed with the MCF7/∆Akt-1(CA)DoxR cells 
although rapamycin-mediated suppression of the 4HT 
IC50s was also observed in doxorubicin sensitive MCF-7 
cells. Thus rapamycin is able to synergize with 4HT in 
these ER+ cells (Table 2).  
Figure 3: effects of co-treatment with doxorubicin, 
4Ht and a mtor Inhibitor. Panel A. The effects of adding 
a constant dose of 50 nM 4HT on the doxorubicin IC50 were 
examined in MCF7/∆Akt-1(CA) cells.  Panel b. The effects of 
adding a constant dose of 1 nM rapamycin on the doxorubicin 
IC50 were examined in MCF7/∆Akt-1(CA) cells. Panel c. The 
effects of adding a constant dose of 1 nM rapamycin on the 4HT 
IC50 were examined in MCF7/∆Akt-1(CA) cells.   The statistical 
significance was determined by the unpaired t test. Comparisons 
determined to be significant are indicated with (***). Panel A. 
The P value between doxorubicin vs. doxorubicin and 50 nM 
4HT treatment of MCF7/∆Akt-1(CA) cells was 0.0001. Panel 
B. The P value between doxorubicin vs. doxorubicin and 1 nM 
rapamycin treatment of MCF7/∆Akt-1(CA) cells was 0.0008. 
Panel C. The P value between 4HT vs. 4HT and 1 nM rapamycin 
treatment of MCF7/∆Akt-1(CA) cells was 0.0001.
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effects of mtor Inhibitors on sensitivity of 
McF-7 cells to doxorubicin
MCF-7 cells were more sensitive to doxorubicin 
than MCF7/∆Akt-1(CA) cells (Figure 4, Panel A). 
However, low doses of rapamycin had greater effects on 
the doxorubicin IC50s in MCF7/∆Akt-1(CA) than in MCF-
7 cells. Essentially a constant dose of 1 nM rapamycin 
did not reduce the IC50 for doxorubicin in MCF-7 cells 
(Figure 4, Panel B), while it did reduce the IC50 for 
doxorubicin in MCF7/∆Akt-1(CA) cells to approximately 
the same IC50 level observed in MCF-7 cells (Panel C). 
effects of mtor Inhibitors on sensitivity of 
MCF-7 and MCF7/∆Akt-1(CA) Cells to Etoposide 
and 4Ht
MCF-7 cells were more sensitive to etoposide 
than MCF-7/∆Akt-1(CA)DoxR cells (Figure 5, Panel 
A). Rapamycin was able to lower  the concentration of 
etoposide required to reach the IC50 in the MCF-7/∆Akt-
1(CA) and MCF-7/∆Akt-1(CA)DoxR cells  (Figure 
5 and Table 2).  Usually a higher degree of interaction 
was observed in the MCF-7/∆Akt-1(CA)DoxR cells. The 
results of addition of 1 nM rapamycin on the etoposide 
IC50s in MCF-7 and MCF-7/∆Akt-1(CA)DoxR cells are 
presented in Panel B. Rapamycin suppressed the etoposide 
IC50s the most in the MCF-7/∆Akt-1(CA)DoxR cells, with 
approximately a 2-fold reduction as compared to MCF-7 
cells (Table 2). 1 nM rapamycin did not suppress the IC50s 
of etoposide in MCF-7 cells (Panel C), but did suppress 
the IC50 for etoposide in MCF-7/∆Akt-1(CA)DoxR cells 
approximately 2.5 fold (Panel D). 
Rapamycin also suppressed the 4HT IC50s in the 
doxorubicin-sensitive and resistant- cells (Table 2). The 
highest level of rapamycin-mediated suppression of the 
4HT IC50s was observed with the MCF-7/∆Akt-1(CA)
DoxR cells although rapamycin-mediated suppression of 
the 4HT IC50s was also observed in doxorubicin-sensitive 
MCF-7 cells.
dIscussIon
In our studies, we examined the effects of three 
chemotherapeutic drugs (doxorubicin, etoposide and 
paclitaxel), one hormonal drug (tamoxifen, 4HT) and 
the signal transduction inhibitor rapamycin on MCF-7 
and derivative cell lines which varied in their levels of 
activated Akt-1 expression. An advantage of our study 
is that all the cells had the same genetic background as 
they all were MCF-7 breast cancer cells, however they 
differed in the levels of activated Akt-1 expression due to 
introduction of an activated Akt-1 gene.
We have previously shown that introduction of 
Figure 4: effects of co-treatment with doxorubicin 
and a mtor Inhibitor. Panel A. The sensitivities of MCF-7 
and MCF7/∆Akt-1(CA) cells to different doses of doxorubicin 
are presented. Panel b. The sensitivity of MCF-7 cells to 
different doses of doxorubicin is compared with the effects 
of doxorubicin and a suboptimal dose of 1 nM rapamycin. 
Panel c. The sensitivities of MCF-7 and MCF7/∆Akt-1(CA) 
cells to different doses of doxorubicin and a suboptimal dose 
of 1 nM rapamycin are shown. The statistical significance was 
determined by the unpaired t test. Comparisons determined to 
be significant are indicated with (***). Panel A. The P value 
between doxorubicin treatment of MCF-7 and MCF7/∆Akt-
1(CA) cells was 0.0005.
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dominant negative (DN) forms of PTEN into MCF-7 
cells conferred resistance to doxorubicin and increased 
sensitivity to rapamycin [9]. Furthermore, rapamycin 
could synergize with doxorubicin to lower its IC50 [9]. In 
the MCF-7 cells transfected cells with the DN PTEN genes, 
increased levels of activated Akt were detected. However, 
these drug-resistant PTEN(DN) transfected cells were 
hypersensitive to rapamycin. These results have clinical 
significance as the PI3K/PTEN/Akt/mTOR pathway is 
often activated in breast cancer by mutations at PIK3CA 
or multiple genetic mechanisms leading to dysregulation 
of PTEN. Furthermore, drug resistance frequently 
develops in breast cancer after chemo- or hormonal-based 
therapies. Doxorubicin (a.k.a Adriamycin) is frequently 
used to treat breast cancer patients. In the studies present 
in this report, increased expression of activated Akt-
1 resulted in the resistance of MCF-7 breast cancer 
cells to both chemotherapeutic drugs (doxorubicin and 
etoposide) as well as hormonal based drugs (4HT) and 
these drug resistant activated Akt-1 overexpressing cells 
were also hypersensitive to rapamycin, which reduced 
the concentrations of doxorubicin, etoposide and 4HT 
required to reach the IC50s in these cells. 
The roles of Akt and downstream mTOR are critical. 
Hyperactivation of mTOR will induce cellular senescence 
which can be inhibited by mTOR inhibitors. mTOR 
appears to be an essential switch which stimulates p53 to 
promote cellular quiescence vs. senescence. [70-75]. 
Doxorubicin, etoposide and paclitaxel all have 
been used to treat breast cancer. However, doxorubicin 
and paclitaxel are more commonly employed in breast 
cancer therapy today than etoposide [76]. Tamoxifen is 
a common hormonal-based drug used to treat ER+ breast 
cancer. After chemotherapeutic drug and hormonal based 
Figure 5: effects of co-treatment with etoposide and rapamycin on etoposide Ic50s. The effects of adding a sub-optimal 
constant dose of 1 nM rapamycin on the etoposide IC50s were examined in MCF-7 and MCF7/∆Akt-1(CA)DoxR cells. Panel A. The 
sensitivity of MCF-7 and MCF7/∆Akt-1(CA)DoxR cells to different doses of etoposide in presented.  Panel b. The sensitivities of MCF-
7 and MCF7/∆Akt-1(CA)DoxR cells to different doses of etoposide and a suboptimal dose of 1 nM rapamycin in presented. Panel c. 
The sensitivity of MCF-7 cells to different doses of etoposide is compared with the effects of etoposide and a suboptimal dose of 1 nM 
rapamycin. Panel d. the sensitivity of MCF7/∆Akt-1(CA)DoxR cells to different doses of etoposide is compared with the effects of 
etoposide and a suboptimal dose of 1 nM rapamycin. Comparisons determined to be significant are indicated with (***). Panel A. The P 
value between etoposide treatment of MCF-7 and MCF7/∆Akt-1(CA)DoxR cells was 0.0003. Panel D. The P value between etoposide and 
etoposide and 1nM rapamycin treatment of MCF7/∆Akt-1(CA)DoxR cells was 0.0005.
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drug treatment of breast cancer patients, resistance will 
develop [10,77]. Thus it is essential to develop new more 
effective and alternative methods to treat breast cancer. 
Doxorubicin, etoposide and paclitaxel can all be 
transported by the same drug transporter (Mdr-1, a.k.a., 
Pgp, and ABCB1) [78]. Our results suggest that Mdr1 is 
not likely to be involved in the drug resistance of these 
cells but our studies do not exclude many other drug 
transporters. Both doxorubicin and etoposide target events 
involved in DNA replication, whereas paclitaxel targets 
microtubules. Therefore it is not surprising that cells 
selected for resistance to doxorubicin are also resistant 
to etoposide, but not paclitaxel. Our studies suggest that 
attention should be given during treatment of breast 
cancer patients who have become resistant to a particular 
chemotherapeutic drug, as these patients may be cross-
resistant to other chemotherapeutic drugs which target 
similar events.
Interestingly, suboptimal doses of 4HT would 
interact with doxorubicin to lower the doxorubicin IC50 
in MCF-7, MCF-7/∆Akt-1(CA), and MCF-7/∆Akt-1(CA)
DoxR approximately 8- to 10-fold. This demonstrates the 
important effects of 4HT on ER cells. Even though cells 
that express activated Akt require more 4HT to reach the 
IC50 than cells which do not express activated Akt, they 
will still respond to 4HT when they are also treated with 
doxorubicin. Thus resistance to doxorubicin does not 
prevent a response to 4HT. 
The mechanisms by which doxorubicin and 
rapamycin synergize to inhibit the growth of breast cancer 
cells are under further investigation. Doxorubicin can 
induce reactive oxygen species (ROS) which have many 
effects on cell growth and the prevention of apoptosis. 
A consequence of doxorubicin treatment may be the 
induction of the Raf/MEK/ERK pathway which may have 
some anti-apoptotic effects [79]. 
The ability of a 1 nM constant addition of the mTOR 
inhibitor rapamycin to interact with 4HT and lower the 
IC50 for 4HT was observed in MCF-7 and MCF-7/∆Akt-
1(CA) cells. In contrast, 1 nM rapamycin did not increase 
the sensitivity of MCF-7 cells to either doxorubicin or 
etoposide. Higher doses of the mTOR inhibitor were 
not examined in these studies as 1 nM rapamycin was 
close to the IC50s previously observed in the cell lines. 1 
nM rapamycin was sufficient to increase the sensitivity 
of MCF-7/∆Akt-1(CA) cells and not MCF-7 cells to 
doxorubicin and etoposide. 
These results are relevant to potential cancer 
therapies as Akt is frequently activated by upstream 
PIK3CA or PTEN mutations or gene silencing. PTEN can 
be mutated or silenced by various mechanisms in human 
cancer. Mutations occur which either delete the PTEN gene 
or alter its activity. Sometimes these mutations actually 
make the cells sensitive to Akt and mTOR inhibitors as 
the growth of the cells becomes dependent upon elevated 
Akt levels and downstream mTOR and p70S6K activities 
[60]. 
MAterIAls And MetHods
cell culture
MCF-7 cells were obtained from the American 
Type Culture Collection (ATCC) (Manassas, VA). Cell 
culture medium for MCF-7 cells consisted of Roswell 
Park Memorial Institute-1640 (RPMI 1640) medium 
(Invitrogen. Carlsbad CA) supplemented with 10% (v/v) 
heat inactivated fetal bovine serum (FBS) as described 
[5].
Akt Plasmids
MCF-7 cells were infected with a retrovirus encoding 
the ∆Akt-1(CA) gene [69,80]. Stably ∆Akt-1(CA)- 
infected or EGFP-transfected MCF-7 cells were isolated 
after growth for 4 weeks in selective drug (2 mg/ml G418, 
Sigma-Aldrich, St. Louis, MO) as described [9,80].
Analysis of sensitivity to drugs and signal 
transduction Inhibitors. 
Cells were seeded in 96-well cell culture plates (BD 
Biosciences) at a density of 5,000 cells/well in 100 µl/well 
of phenol red free RPMI-1640 containing 5% charcoal 
stripped (CS) FBS as described [5]. Cells were incubated 
for 1 day to permit cells to adhere to the bottom of each 
well. Cells were subsequently treated with serial 2-fold 
dilutions of the chemotherapeutic drugs (doxorubicin, 
etoposide or paclitaxel), the hormonal drug (4HT), signal 
transduction inhibitor, rapamycin, (all purchased from 
Sigma-Aldrich) or a constant suboptimal concentration of 
the hormonal drug or signal transduction inhibitor. Cells 
were incubated for an additional 4 days at 37 °C until 
extent of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT, Sigma-Aldrich) reduction in 
each well was quantified at 530 nm [5]. 
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